Q-omics provides the consensus-scored NXT2 profile across patient tissues and cancer cell-line models. NXT2 expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, NXT2 is differentially expressed in 15, with the highest sampling consensus in BLCA. Additionally, NXT2 protein abundance shows 29,425 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight SKCM, BLCA, and LSCC as cancer lineages where NXT2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NXT2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NXT2 survival associations across molecular data types. NXT2 RNA expression shows survival associations in the most cancer types (28), followed by mutation status (2) and mass-spec protein abundance (11). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NXT2 RNA expression–survival associations across cancer types. High NXT2 expression shows unfavorable associations in ACC, KICH, PAAD, SARC and KIRP, but favorable associations in SKCM. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for NXT2 RNA expression.
This table summarizes NXT2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 11. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for NXT2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NXT2 shows lower tumor expression in THCA and KICH and higher tumor expression in BLCA, HNSC, LIHC and KIRC. The BLCA box plot shows higher NXT2 RNA expression in tumor versus normal tissue (log2 FC = +1.009, t-test p < 0.001).
This table shows molecular features associated with NXT2 in patient tissues and cancer cell lines. In patient samples, NXT2 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, NXT2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and UPPER_AERODIGESTIVE_TRACT.
